Sponsored by
Northwest Bio has announced plans to apply for approval of DCVax within the coming month. Following the submission, the approval process is expected to take approximately 150 business days. This represents a significant milestone for the company. DCVax is a dendritic cell-based vaccine that is personalized to an individual's tumor. To create the vaccine, a sample of the tumor is required. The results from a large Phase 3 trial have been highly promising, and preliminary data from ongoing trials involving combination therapies appear to be remarkable.